Citizens JMP raised the firm’s price target on Privia Health (PRVA) to $31 from $30 and keeps an Outperform rating on the shares. Privia Health fired on all cylinders in Q3, with most key operating and financial metrics exceeding expectations, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- Privia Health Reports Strong Q3 2025 Results
- Privia Health Group: Strong Financial Performance and Strategic Growth Justify Buy Rating
- Privia Health files automatic mixed securities shelf
- Privia Health Group: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Privia Health raises FY25 revenue view to $2.05B-$2.1B from $1.8B-$1.9B